TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.

LEARNING OBJECTIVES

• Recall available data supporting the use of anti-PD-1 antibody therapy for bacillus Calmette-Guérin–resistant, high-risk, non-muscle-invasive bladder cancer (NMIBC), and determine how this strategy can be appropriately integrated into current care.
• Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this treatment strategy.
• Appreciate the impact of biologic and patient-specific factors on the selection and sequencing of treatment for patients with metastatic urothelial bladder cancer (mUBC).
• Evaluate available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed mUBC.
• Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients who may benefit from these approaches.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
• Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for patients with NMIBC, MIBC and mUBC.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:

FACULTY

Shilpa Gupta, MD
Associate Professor
Director, Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Advisory Committee: Aveo Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Lilly, Pfizer Inc; Consulting Agreements: Aveo Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Pfizer Inc; Ownership Interest: Nektar; Speakers Bureau: Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Seagen Inc.

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale School of Medicine
New Haven, Connecticut

Consulting Agreements: Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc; Contracted Research: Gilead Sciences Inc.

Guru Sonpavde, MD
Bladder Cancer Director
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Sanofi Genzyme, Scholar Rock, Seagen Inc; Consulting Agreements (Paid): AstraZeneca Pharmaceuticals LP, Debiopharm, EMD Serono Inc; Consulting Agreements (Unpaid): Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, QED Therapeutics, Seagen Inc; Travel Cost: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Writing/Editor Fees: Elsevier Practice Update Bladder Cancer Center of Excellence.

Moderator

Sumanta Kumar Pal, MD
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope
Duarte, California

No relevant conflicts of interest to disclose.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Gilead Sciences Inc.

Release date: March 2022
Expiration date: March 2023